Skip to main content
Caplight Logo









SYnAbs SA

SYnAbs SA

Private
BelgiumHealthcare & Life Scienceshttps://www.synabs.be/

Last Round

Grant

Dec 1, 2022

Total Funding Raised

$630,000

Company Overview

SYnAbs SA is a biotechnology company that specializes in the development and production of innovative monoclonal antibodies for research, diagnostic, and therapeutic applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Biotech Equipment

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

monoclonal antibodiesmAbcontract research organizationCROantibody generationimmunoassay developmentin vitro diagnosticIVDcustom antibody servicebiotech servicesantibody discoveryimmunology toolsaffinity purificationisotype controlsdrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SYnAbs SA Comparables

Compare SYnAbs SA with similar companies based on industry and business-model similarity.

SYnAbs SA comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Creative Biolabs
85%
Precision Antibody
82%
BIOTEM
81%

SYnAbs SA Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantDec 1, 2022
GrantMar 19, 2021
SeedSep 14, 2015

Key People

Founding team and executive leadership

Julien Isoard

Chairman & CEO

Executive Team

SYnAbs SA Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 13, 2025

    Developing monoclonal antibodies for HbC-specific detection.

  • Dec 1, 2022

    $630K grant round led by European Innovation Council Fund.

SYnAbs SA Filings

Explore SEC and related filing metadata, where available.

SYnAbs SA filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about SYnAbs SA's valuation, stock price, and market status.

Is SYnAbs SA a public or private company?

SYnAbs SA is a private company.

What is the current stock price of SYnAbs SA?

SYnAbs SA is a private company with no public stock price. No recent secondary market data is available.

How much is SYnAbs SA worth (valuation)?

Valuation information for SYnAbs SA is not publicly available.

Can I buy SYnAbs SA stock?

SYnAbs SA shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was SYnAbs SA's last funding round?

SYnAbs SA's most recent funding round was Grant on December 1, 2022.

Who are the main investors in SYnAbs SA?

Key investors in SYnAbs SA include European Innovation Council Fund, Biotech Investissement, Walloon Region (Belgium).

Will SYnAbs SA IPO soon?

No public IPO plans have been announced for SYnAbs SA.

How can I track SYnAbs SA secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor SYnAbs SA's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBelgium
Employee Range4
Year Founded2015
Last FundingDec 1, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?